Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry

被引:49
|
作者
Clarke, Lorne A. [1 ]
Giugliani, Roberto [2 ]
Guffon, Nathalie [3 ]
Jones, Simon A. [4 ]
Keenan, Hillary A. [5 ]
Munoz-Rojas, Maria, V [5 ]
Okuyama, Torayuki [6 ]
Viskochil, David [7 ]
Whitley, Chester B. [8 ,9 ]
Wijburg, Frits A. [10 ]
Muenzer, Joseph [11 ]
机构
[1] Univ British Columbia, BC Childrens Hosp Res Inst, Dept Med Genet, Vancouver, BC, Canada
[2] Fed Univ Rio Grande & Med Genet Serv, Dept Genet, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[3] Hop Femme Mere Enfant, Ctr Reference Malad Hereditaires Metab, Bron, France
[4] Manchester Univ NHS Trust, Manchester Ctr Genom Med, Manchester, Lancs, England
[5] Sanofi Genzyme, Cambridge, MA USA
[6] Natl Ctr Child Hlth & Dev, Dept Clin Lab Med, Tokyo, Japan
[7] Univ Utah, Salt Lake City, UT USA
[8] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[9] Univ Minnesota, Expt & Clin Pharmacol, Minneapolis, MN USA
[10] Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands
[11] Univ N Carolina, Chapel Hill, NC 27515 USA
关键词
genotype-phenotype; hurler syndrome; iduronidase; lysosomal storage disease; lysosome; metabolic disease; mucopolysaccharidosis; Scheie syndrome; ALPHA-L-IDURONIDASE; IDENTIFICATION; DIAGNOSIS;
D O I
10.1111/cge.13583
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disorder resulting from pathogenic variants in the alpha-L-iduronidase (IDUA) gene. Clinical phenotypes range from severe (Hurler syndrome) to attenuated (Hurler-Scheie and Scheie syndromes) and vary in age of onset, severity, and rate of progression. Defining the phenotype at diagnosis is essential for disease management. To date, no systematic analysis of genotype-phenotype correlation in large MPS I cohorts have been performed. Understanding genotype-phenotype is critical now that newborn screening for MPS I is being implemented. Data from 538 patients from the MPS I Registry (380 severe, 158 attenuated) who had 2 IDUA alleles identified were examined. In the 1076 alleles identified, 148 pathogenic variants were reported; of those, 75 were unique. Of the 538 genotypes, 147 (27%) were unique; 40% of patients with attenuated and 22% of patients with severe MPS I had unique genotypes. About 67.6% of severe patients had genotypes where both variants identified are predicted to severely disrupt protein/gene function and 96.1% of attenuated patients had at least one missense or intronic variant. This dataset illustrates a close genotype/phenotype correlation in MPS I but the presence of unique IDUA missense variants remains a challenge for disease prediction.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 50 条
  • [21] Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry
    Polgreen, Lynda E.
    Bay, Luisa
    Clarke, Lorne A.
    Guffon, Nathalie
    Jones, Simon A.
    Muenzer, Joseph
    Flores, Ana Lorena
    Wilson, Kathryn
    Viskochil, David
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2022, 188 (10) : 2941 - 2951
  • [22] Genotype-phenotype relationships in patients with type I hyperlipoproteinemia
    Chokshi, Neema
    Blumenschein, Sarah D.
    Ahmad, Zahid
    Garg, Abhimanyu
    JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) : 287 - 295
  • [23] Qualitative interviews with patients with mucopolysaccharidosis type I (MPS I) and caregivers to evaluate the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ)
    Pabla, Anureet K.
    Litcher-Kelly, Leighann
    Pollissard, Laurence
    Yaworsky, Andrew
    Ollis, Sarah
    Kelly, Masami
    Padilla, Brad
    Hamed, Alaa
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S114 - S114
  • [24] Mucopolysaccharidosis type I (MPS I)-genetic analysis of 38 Italian patients
    Venturi, N
    Parini, R
    Menni, F
    Corti, P
    Rovelli, A
    Bertagnolio, B
    Uziel, G
    Gatti, R
    Camo, F
    Brambillasca, F
    Furlan, F
    Donati, MA
    Biondi, A
    Goldwurm, S
    PEDIATRIC RESEARCH, 2003, 54 (04) : 616 - 616
  • [25] Liver-Directed Gene Therapy for Mucopolysaccharidosis Type I (MPS I)
    Gurda, Brittney
    Bell, Peter
    Zhu, Yanqing
    Wang, Ping
    O'Donnell, Patty
    Sanmiguel, Julio
    Vandenberghe, Luk
    Haskins, Mark
    Wilson, James
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S32 - S32
  • [26] Genotype-phenotype correspondence in mucopolysaccharidosis type I and the implications for newborn screening
    Whitley, Chester B.
    Moss, Timothy J.
    Gaviglio, Amy
    Wiens, Katie A.
    Schema, Lynn
    Ou, Li
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S147 - S147
  • [27] IDUA mutational profile and genotype-phenotype correlations in mucopolysaccharidosis type I
    Ghosh, Arunabha
    Mercer, Jean
    Jones, Simon A.
    Church, Heather
    Tylee, Karen
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S49 - S50
  • [28] The MPS I Registry.
    Clarke, JTR
    Pastores, GM
    Viskochil, D
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 453 - 453
  • [29] Liver-Directed Gene Therapy for Mucopolysaccharidosis Type I (MPS I)
    Gurda, Brittney L.
    Bell, Peter
    Wang, Ping
    Zhu, Yanqing
    O'Donnell, Patty
    Vandenberghe, Luk H.
    Calcedo, Roberto
    Sanmiguel, Julio
    Haskins, Mark E.
    Wilson, James M.
    MOLECULAR THERAPY, 2012, 20 : S123 - S124
  • [30] MPS I and carpal tunnel syndrome: analysis using the MPS I Registry
    Guffon, Nathalie
    Viskochil, David
    Hutchinson, Douglas T.
    Garin, Christophe
    Moy, Kristin A.
    Munoz-Rojas, M. Veronica
    Muenzer, Joseph
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S59 - S60